p53 in drug resistance in ovarian cancer [20]

Lancet

Volumn 349, Issue 9064, 1997, Pages 1556-

  Lavarino, C ^a   Delia, D ^a   Di Palma, S ^a   Zunino, F ^a   Pilotti, S ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; PACLITAXEL; PROTEIN P53;

APOPTOSIS; CLINICAL ARTICLE; DNA DAMAGE; FEMALE; GENE MUTATION; HUMAN; IMMUNOCYTOCHEMISTRY; LETTER; MISSENSE MUTATION; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SECOND LOOK SURGERY; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE;

EID: 0031009631     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62140-X     Document Type: Letter

References (5)

1. AN Shelling Role of p53 in drug resistance in ovarian cancer Lancet 349 1997 744 745
2. SC Righetti G Della Torre S Pilotti A comparative study of p53 gene mutations, protein accumulation and response to cisplatin-based chemotherapy in advanced ovarian carcinoma Cancer Res 56 1996 689 693
3. AF Wahl KL Donaldson C Fairchild Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis Nat Med 2 1996 72 79
4. D Debernardis EG Siré P De Feudis p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel Cancer Res 57 1997 870 874
5. D Delia S Mizutani G Lamorte K Goi S Iwata MA Pierotti p53 activity and chemotherapy Nat Med 2 1996 724 725